Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alnylam Pharma ( (ALNY) ) has provided an announcement.
Alnylam Pharma has engaged in financial maneuvers involving convertible senior notes. The company offered and sold notes to initial purchasers under exemptions from registration, with potential issuance of up to 1,381,483 shares of common stock upon conversion. Concurrently, Alnylam executed note repurchase transactions, buying back approximately $637.8 million of its 1.00% convertible senior notes due 2027 for around $1,105.8 million, influenced by market conditions.
The most recent analyst rating on (ALNY) stock is a Buy with a $515.05 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.
Spark’s Take on ALNY Stock
According to Spark, TipRanks’ AI Analyst, ALNY is a Neutral.
Alnylam Pharma’s overall stock score is primarily influenced by its strong earnings call performance, which highlights significant revenue growth and positive future guidance. However, financial performance remains a concern due to high leverage and negative profitability, which are significant risks. Technical analysis indicates strong momentum but warns of potential overbought conditions. Valuation metrics are weak due to negative earnings and lack of dividends.
To see Spark’s full report on ALNY stock, click here.
More about Alnylam Pharma
Average Trading Volume: 1,119,265
Technical Sentiment Signal: Buy
Current Market Cap: $61.42B
See more insights into ALNY stock on TipRanks’ Stock Analysis page.